Michelle J. Henderson

New South Wales Department of Health — Australia

Medicine · Health Sciences

31h-index4.3kcitations123works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(46), Acute Lymphoblastic Leukemia research(30), Protein Degradation and Inhibitors(22), Histone Deacetylase Inhibitors Research(20), Cancer therapeutics and mechanisms(17)

Publications121 total

Blinatumomab in de novo AYA ALL—Results of the Australasian Leukaemia and Lymphoma Group ALL09 “SUBLIME” study
HemaSphere·2026Open Access
Measurable Residual Disease detection in Acute Lymphoblastic Leukaemia - comparison between targeted NGS and ASO-RQPCR
Pathology·2025
High Expression of <i>NTRK1</i> in <i>ETV6::RUNX1</i> Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib
Pediatric Blood & Cancer·2025
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia
Blood Cancer Journal·2024· 5 citedOpen Access
Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol
Blood Neoplasia·2024· 2 citedOpen Access
Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients
Molecular Cancer·2024· 6 citedOpen Access
FDA-approved disulfiram as a novel treatment for aggressive leukemia
Journal of Molecular Medicine·2024· 13 citedOpen Access
Measurable residual disease detection in acute lymphoblastic leukaemia – comparison between NGS and ASO-qPCR
Pathology·2024· 1 citedOpen Access
Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies
Blood·2023
Distinct Pattern of ABL1 Genomic Breakpoints in Chronic Myeloid Leukemia and BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Analysis of 884 Patients with Minor and Major BCR::ABL1 Fusion
Blood·2023Open Access
Data from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Tables 1-5 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Video S3 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Video S2 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Data from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant &lt;i&gt;MLL&lt;/i&gt;-Rearranged Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Tables 1-5 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Figures S1-S5 from A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers
2023Open Access
Supplementary Video S4 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Supplementary Figures from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
2023Open Access
Data from A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Murray D. Norris(32), Michelle Haber(31), Amanda J. Russell(14), Rosemary Sutton(10), Angelika Bongers(10), Jamie I. Fletcher(9), Chelsea Mayoh(9), Klaartje Somers(9), Anna DeFazio(8), Ursula R. Kees(8), Andrei V. Gudkov(8), Richard B. Lock(8), Mawar Karsa(8), Marcia A. Munoz(7), Glenn M. Marshall(7), Claudia L. Flemming(6), David D.L. Bowtell(6), MoonSun Jung(6), Nicola C. Venn(6), Colin K. W. Watts(6)